Assessing Cidara Therapeutics' (CDTX) Valuation After a 137% Surge
ByAinvest
Tuesday, Nov 25, 2025 7:46 am ET1min read
CDTX--
Cidara Therapeutics (CDTX) has surged 137% in one month, with a 1,078% total shareholder return over the last year. The company's price-to-book ratio is 16.4x, significantly higher than peers and the industry average. Our discounted cash flow model suggests the shares are trading 46% below estimated fair value, potentially indicating an underappreciation of future cash flows. However, the company's valuation and minimal revenue make it vulnerable to disappointing news or delayed growth.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet